Reto Agosti

Zollikon, ZH 8702, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Swiss Quality of Life and Health Care Impact Assessment in a Real-World Erenumab-Treated Migraine Population: Results over 2 years.

Swiss Quality of Life and Health Care Impact Assessment in a Real-World Erenumab-Treated Migraine Population: Results over 2 years.

Journal: Headache

Published: September 26, 2024

Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.

Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.

Journal: Journal of neurology

Published: March 05, 2024

Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study.

Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study.

Journal: Pain and therapy

Published: December 23, 2022

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Journal: The journal of headache and pain

Published: December 19, 2022

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Journal: The journal of headache and pain

Published: July 26, 2022

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.

Journal: Cephalalgia : an international journal of headache

Published: May 18, 2021

Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.

Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.

Journal: Pharmacoepidemiology and drug safety

Published: March 15, 2019

Treatment patterns in patients using triptan and prophylactic medication: an analysis of clinical practice prior to the introduction of CGRP antagonists.

Treatment patterns in patients using triptan and prophylactic medication: an analysis of clinical practice prior to the introduction of CGRP antagonists.

Journal: Journal of pain research

Published: March 05, 2019

Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View.

Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View.

Journal: Headache

Published: February 28, 2018

Ketamine i. v. for the treatment of cluster headaches : An observational study

Ketamine i. v. for the treatment of cluster headaches : An observational study

Journal: Schmerz (Berlin, Germany)

Published: April 13, 2016

Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine.

Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: August 10, 2013

Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker.

Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker.

Journal: SpringerPlus

Published: January 25, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026